Table 1

Cumulative incidence based on baseline serum urate groups for the entire group, men and women for each follow-up period

Baseline urate (mg/dL)	n	3 years			5 years			10 years			15 years
Baseline urate (mg/dL)	n	Incidence (%)	Lower 95% CI	Upper 95% CI	Incidence (%)	Lower 95% CI	Upper 95% CI	Incidence (%)	Lower 95% CI	Upper 95% CI	Incidence (%)	Lower 95% CI	Upper 95% CI
All participants
<6.0	12 103	0.21	0.13	0.29	0.33	0.23	0.43	0.79	0.63	0.96	1.12	0.90	1.35
6.0–6.9	3848	0.37	0.18	0.56	0.66	0.40	0.92	1.98	1.47	2.48	3.70	2.79	4.62
7.0–7.9	1870	0.92	0.49	1.36	1.91	1.28	2.54	6.37	4.94	7.80	9.00	6.93	11.06
8.0–8.9	758	4.00	2.59	5.40	6.94	5.12	8.76	11.32	8.84	13.79	16.28	12.00	20.55
9.0–9.9	230	8.31	4.73	11.89	14.02	9.51	18.52	24.18	16.55	31.82	35.21	21.94	48.48
≥10.0	80	10.00	3.43	16.57	26.25	16.61	35.89	40.00	29.26	50.74	48.57	30.50	66.64
Overall	18 889	0.60	0.40	0.80	1.10	0.90	1.30	2.40	2.20	2.60	3.20	2.81	3.59
Men
<6.0	3538	0.35	0.15	0.54	0.52	0.28	0.77	1.04	0.69	1.40	1.55	1.05	2.04
6.0–6.9	2563	0.44	0.18	0.69	0.80	0.45	1.14	2.12	1.49	2.76	4.04	2.94	5.14
7.0–7.9	1388	0.95	0.44	1.46	2.06	1.30	2.81	5.51	4.10	6.91	8.23	6.07	10.38
8.0–8.9	581	5.03	3.25	6.82	7.82	5.63	10.02	11.51	8.87	14.15	15.69	11.31	20.07
9.0–9.9	161	10.03	5.37	14.70	13.81	8.45	19.17	25.41	16.35	34.47	34.18	20.24	48.13
≥10.0	49	14.29	4.49	24.08	28.57	15.92	41.22	36.73	23.24	50.23	47.28	25.31	69.24
Overall	8280	1.08	0.86	1.31	1.82	1.53	2.11	3.50	3.07	3.93	4.94	4.34	5.54
Women
<6.0	8565	0.15	0.07	0.24	0.25	0.14	0.36	0.69	0.51	0.88	0.95	0.70	1.20
6.0–6.9	1285	0.24	0.00	0.51	0.40	0.05	0.75	1.58	0.88	2.29	2.53	1.04	4.02
7.0–7.9	482	0.84	0.02	1.67	1.49	0.39	2.59	10.47	5.50	15.44	12.42	6.26	18.57
8.0–8.9	177	0.57	0.00	1.68	4.05	1.11	6.98	11.08	4.36	17.80	20.44	6.78	34.10
9.0–9.9	69	4.35	0.00	9.16	14.49	6.19	22.80	18.84	9.61	28.07	39.13	4.00	74.26
≥10.0	31	3.23	0.00	9.45	22.58	7.86	37.30	45.16	27.64	62.68	45.16	27.64	62.68
Overall	10 609	0.24	0.15	0.33	0.55	0.41	0.69	1.51	1.25	1.76	1.90	1.58	2.22